Safety of antidepressants in the elderly

Expert Opinion on Drug Safety

Volumn 2, Issue 4, 2003, Pages 367-383

  Sommer, Barbara R ^a   Fenn, Howard ^a   Pompei, Peter ^a   DeBattista, Charles ^a   Lembke, Anna ^a   Wang, Po ^a   Flores, Ben ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antidepressants; bupropion; elderly; mirtazapine; monoamine oxidase inhibitors (MAOIs); selective serotonin re uptake inhibitors (SSRIs); side effects; tricyclics; venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGED; DEPRESSION; DRUG INTERACTION; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW;

AGED; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSIVE DISORDER; DRUG INTERACTIONS; HUMANS; MONOAMINE OXIDASE INHIBITORS; SEROTONIN UPTAKE INHIBITORS;

EID: 0141595197     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2.4.367     Document Type: Review

References (98)

1. VESTAL RE: Aging and pharmacology. Cancer (1997) 80:1302-1310. (Pubitemid 27407233)
2. SEMLA TP: Essentials of geriatric pharmacotherapy. Resid. Staff Physician (2002) 48(2):25-31.
3. VON MOLTKE LL, GREENBLATT DJ: Drug transporters revisited. J. Clin. Psychopharmacol. (2001) 21:1-3. (Pubitemid 32096742)
4. GREENBLATT DJ, PATKI KC, VON MOLTKE LL, SHADER RI: Drug interactions with grapefruit juice: an update. J. Clin. Psychopharmacol. (2001) 21(4):357-359. (Pubitemid 32673023)
5. KETTER TA, FLOCKHART DA, POST RM et al.: The emerging role of cytochrome P450 3A in psychopharmacology. J. Clin. Psychopharmacol. (1995) 15:387-398. (Pubitemid 26005587)
6. POLLOCK BG: Adverse reactions of antidepressants in elderly patients. J. Clin. Psychiatry (1999) 60(Suppl. 20):4-8. (Pubitemid 29468383)
7. COTE LJ, KREMZNER LT: Biochemical changes in normal aging in human brain. In: The Dementias. Mayeux R, Rosen W (Eds), Raven Press, New York (1983):19-30.
8. BEERS MH: Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch. Intern. Med. (1997) 157:1531-1536. (Pubitemid 27305197)
9. DAVIDSON J: Pharmacological treatment. In: Textbook of Geriatric Psychiatry (2nd edn). Busse EW, Blazer DG (Eds), American Psychiatric Association Press, Washington DC (1996):364.
10. KATZ IR, SIMPSON GM, JETHANANDANI V, COOPER T, MUHLY C: Steady state pharmacokinetics of nortriptyline in the frail elderly. Neuropsychopharmacology (1989) 2(3):229-236. (Pubitemid 19248315)
11. KUMAR V, SMITH RC, REED K, LEELAVATHI DE: Plasma levels and effects of nortriptyline in geriatric depressed patients. Acta Psychiatr. Scand. (1987) 75(1):20-28. (Pubitemid 17019548)
12. NELSON JC, MAZURE CM, JATLOWPI: Desipramine treatment of major depression in patients over 75 years of age. J. Clin. Psychopharmacol. (1995) 15(2):99-105.
13. NIES A, ROBINSON DS, FRIEDMAN MJ et al.: Relationship between age and tricyclic antidepressant plasma levels. Am. J. Psychiatry (1977) 134(7):790-793. (Pubitemid 8137219)
14. SOLAI LK, MULSANT BH, POLLOCK BG et al.: Effect of sertraline on plasma nortriptyline levels in depressed elderly. J. Clin. Psychiatry (1997) 58(10):440-443. (Pubitemid 27485622)
15. HOLROYD KA, O'DONNELL FJ, STENSLAND M, LIPCHIK GL, CORDINGLEY GE, CARLSON BW: Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination: a randomized controlled trial. JAMA (2001) 285(17):2208-2215. (Pubitemid 32416766)
16. PANERAI AE, MONZA G, MOVILIA P, BIANCHI M, FRANCUCCI BM, TIENGO M: A randomized, within-patient, cross-over, placebo-controlled trial on the efficacy and tolerability of the tricyclic antidepressants chlorimipramine and nortriptyline in central pain. Acta Neurol. Scand. (1990) 82(1):34-38. (Pubitemid 20249249)
17. WATSON CP, EVANS RJ, REED K, MERSKEY H, GOLDSMITH L, WARSH J: Amitriptyline versus placebo in postherpetic neuralgia. Neurology (1982) 32(6):671-673. (Pubitemid 12119035)
18. ATKINSON JH, SLATER MA, WILLIAMS RA et al.: A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain (1998) 76(3):287-296. (Pubitemid 28342738)
19. MULSANT BH, POLLOCK BG, NEBES R et al.: A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients. Am. J. Geriatr. Psychiatry (2001) 9(4):406-414. (Pubitemid 33015128)
20. POLLOCK BG, MULSANT BH, NEBES R et al.: Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline. Am. J. Psychiatry (1998) 155(8):1110-1112. (Pubitemid 28357741)
21. KNEGTERING H, EIJCK M, HUIJSMAN A: Effects of antidepressants on cognitive functioning of elderly patients. A review. Drugs Aging (1994) 5(3):192-199. (Pubitemid 2132660)
22. YOUNG RC, MATTIS S, ALEXOPOULOS GS, MEYERS BS, SHINDLEDECKER RD, DHAR AK: Verbal memory and plasma drug concentrations in elderly depressives treated with nortriptyline. Psychopharmacol. Bull. (1991) 27(3):291-294.
23. MAMO DC, SWEET RA, MULSANT BH et al.: Effect of nortriptyline and paroxetine on extrapyramidal signs and symptoms: a prospective double-blind study in depressed elderly patients. Am. J. Geriatr. Psychiatry (2000) 8(3):226-231. (Pubitemid 30457567)
24. MILLER MD, CURTISS EI, MARINO L et al.: Long-term ECG changes in depressed elderly patients treated with nortriptyline. A double-blind, randomized, placebo-controlled evaluation. Am. J. Geriatr. Psychiatry (1998) 6(1):59-66. (Pubitemid 28051722)
25. MCCUE R, GEROGOTAS A, NAGACHANDRAN N et al.: Plasma levels of nortriptyline and 10-hydroxynortriptyline and treatment-related electrocardiographic changes in the elderly depressed. J. Psychiatr. Res. (1989) 23(1):73-79. (Pubitemid 19191586)
26. DRAGANICH LF, ZACNY J, KLAFTA J, KARRISON T: The effects of antidepressants on obstructed and unobstructed gait in healthy elderly people. J. Gerontol. A. Biol. Sci. Med. Sci. (2001) 56(1):M36-M41. (Pubitemid 32042967)
27. BERNSTEIN J: Handbook of Drug Therapy in Psychiatry (3rd edn). Mosby-Year Book, Inc., St Louis, Missouri (1995):153-180.
28. GARERI P, STILO G, BEVACQUA I, MATTACE R, FERRERI G, DE SARRO G: Antidepressant drugs in the elderly. Gen. Pharmacol. (1998) 30(4):465-475. (Pubitemid 28102820)
29. GARERI P, FALCONI U, DE FAZIO P, DE SARRO G: Conventional and new antidepressant drugs in the elderly. Prog. Neurobiol. (2000) 61:353-396. (Pubitemid 30155726)
30. BALON R, MUFTI R, ARFKEN CL: A survey of prescribing practices for monoamine oxidase inhibitors. Psychiatr. Serv. (1999) 50(7):945-947. (Pubitemid 29309869)
31. SMALL GW: Treatment of geriatric depression. Depress. Anxiety (1998) 8(Suppl. 1):32-42. (Pubitemid 28524844)
32. ROSENZWEIG P, PATAT A, ZIELENIUK I, CIMAROSTI I, ALLAIN H, GANDON JM: Cognitive performance in elderly subjects after a single dose of befloxatone, a new reversible selective monoamine oxidase A inhibitor. Clin. Pharmacol. Ther. (1998) 64(2):211-222. (Pubitemid 28423857)
33. ROOSE SP, GLASSMAN AH, ATTIA E, WOODRING S: Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am. J. Psychiatry (1994) 151(12):1735-1739. (Pubitemid 24370892)
34. LIU BA, MITTMANN N, KNOWLES N, SANDRA R, SHEAR NH: Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. CMAJ (1996) 155(5):519-527. (Pubitemid 26316956)
35. ENSRUD KE, BLACKWELL TL, MANGIONE CM et al.: Central nervous system-active medications and risk for falls in older women. J. Am. Geriatr. Soc. (2002) 50(10):1629-1637. (Pubitemid 35192533)
36. AGOSTINI JV, TINITTI ME: Drugs and falls: rethinking the approach to medication risk in older adults. J. Am. Geriatr. Soc. (2002) 50(10):1744-1745. (Pubitemid 35192551)
37. LEIPZIG RM, CUMMING RG, TINETTI ME: Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J. Am. Geriatr. Soc. (1999) 47(1):30-39. (Pubitemid 29044264)
38. THAPA PB, GIDEON, P, COST TW et al.: Antidepressants and the risk of falls among nursing home residents. N. Engl. J. Med. (1998) 339:875-882. (Pubitemid 28446845)
39. JOO JH, LENZE EJ, MULSANT BH et al.: Risk factors for falls during treatment of late-life depression. J. Clin. Psychiatry (2002) 63(10):936-941. (Pubitemid 35231735)
40. SCHATZBERG AF, COLE JO, DE BATTISTA C: Pharmacological treatment. In: Manual of Clinical Psychopharmacology (3rd edn). American Psychiatric Association Press, Washington DC (1997):72,82.
41. KAPUR S, REMINGTON G: Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry (1996) 153(4):466-476. (Pubitemid 26113309)
42. DELL'AGNELLO G, CERAVOLO R, NUTI A et al.: SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin. Neuropharmacol. (2001) 24(4):221-227. (Pubitemid 32717856)
43. ALEXOPOULOS GS, KATZ IR, REYNOLDS CF, CARPENTER D, DOCHERTY JP: Pharmacotherapy of depressive disorders in older patients. In: The Expert Consensus Guideline Series: Postgraduate Medicine Special Report. McGraw Hill, New York (2001):1-86.
44. LANE R, BALDWIN D: Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J. Clin. Psychopharmacol. (1997) 17(3):208-221. (Pubitemid 27261777)
45. BYMASTER FP, ZHANG W, CARTER PA et al.: Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (2002) 60(4):353-361. (Pubitemid 34253277)
46. STRIK JJ, HONIG A, LOUSBERG R et al.: Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom. Med. (2000) 62(6):783-789. (Pubitemid 32009084)
47. ROOSE SP, GLASSMAN AH, ATTIA E, WOODRING S, GIARDINA EG, BIGGER JT Jr: Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am. J. Psychiatry (1998) 155(5):660-665. (Pubitemid 28225407)
48. WIART L, PETIT H, JOSEPH PA, MAZAUX JM, BARAT M: Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke (2000) 31(8):1829-1832. (Pubitemid 30620458)
49. CONNOLLY VM, GALLAGHER A, KESSON CM: A study of fluoxetine in obese elderly patients with type 2 diabetes. Diabet. Med. (1995) 12(5):416-418.
50. FINKEL SI, RICHTER EM, CLARY CM, BATZAR E: Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression. Am. J. Geriatr. Psychiatry (1999) 7(3):221-227. (Pubitemid 29302961)
51. RONFELD RA, TREMAINE LM, WILNER KD: Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin. Pharmacokinet. (1997) 32(Suppl. 1):22-30. (Pubitemid 27107716)
52. RODRIGUEZ DE LA TORRE B, DREHER J, MALEVANY I et al.: Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther. Drug. Monit. (2001) 23(4):435-440. (Pubitemid 32708931)
53. ROOSE SP, LAGHRISSI-THODE F, KENNEDY JS et al.: Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA (1998) 279(4):287-291. (Pubitemid 28071019)
54. NELSON JC, KENNEDY JS, POLLOCK BG et al.: Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. Am. J. Psychiatry (1999) 156(7):1024-1028. (Pubitemid 29302794)
55. POLLOCK BG, MULSANT BH, NEBES R et al.: Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline. Am. J. Psychiatry (1998) 155(8):1110-1112. (Pubitemid 28357741)
56. FURLAN PM, KALLAN MJ, TEN HAVE T, POLLOCK BG, KATZ I, LUCKI I: Cognitive and psychomotor effects of paroxetine and sertraline on healthy elderly volunteers. Am. J. Geriatr. Psychiatry (2001) 9(4):429-438. (Pubitemid 33015131)
57. MAMO DC, POLLOCK BG, MULSANT B et al.: Effects of nortriptyline and paroxetine on postural sway in depressed elderly patients. Am. J. Geriatr. Psychiatry (2002) 10(2):199-205. (Pubitemid 34685632)
58. LAGHRISSI-THODE F, POLLOCK BG, MILLER MC, MULSANT BH, ALTIERI L, FINKEL MS: Double-blind comparison of paroxetine and nortriptyline on the postural stability of late-life depressed patients. Psychopharmacol. Bull. (1995) 31(4):659-663. (Pubitemid 26091732)
59. DRAGANICH LF, ZACNY J, KLAFTA J, KARRISON T: The effects of antidepressants on obstructed and unobstructed gait in healthy elderly people. J. Gerontol. A. Biol. Sci. Med. Sci. (2001) 56(1):M36-M41. (Pubitemid 32042967)
60. DUNBAR GC: Paroxetine in the elderly: a comparative meta-analysis against standard antidepressant pharmacotherapy. Pharmacology (1995) 51(3):137-144.
61. WILLETTS J, LIPPA A, BEER B: Clinical development of citalopram. J. Clin. Psychopharmacol. (1999) 19(5 Suppl. 1):S36-S46.
62. LIPPA AS, BEER B, CANCR R: Introduction: overview of citalopram. J. Clin. Psychopharmacol. (1999) 19(5 Suppl. 1):S1-S3.
63. POPIK P: Preclinical pharmacology of citalopram. J. Clin. Psychopharmacol.(1999) 19(5 Suppl. 1):S4-S22.
64. PERSONNE M, PERSSON H, SJOBERG G: Citalopram toxicity. Lancet (1997) 350:518-519.
65. KLYSNER R, BENT-HANSEN J, HANSEN HL, LUNDE M, PLEIDRUP E, POULSEN D et al.: Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br. J. Psychiatry (2002) 181:29-35. (Pubitemid 34717835)
66. KYLE CJ, PETERSEN HEH, OVERO KF: Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depress. Anxiety (1998) 8:147-153. (Pubitemid 29016524)
67. THOMAS KV, HOLIMON TD: Citalopram versus other selective serotonin-reuptake inhibitors. Am. J. Health Sys. Pharm. (1999) 56(21):2242-2244. (Pubitemid 29531733)
68. GREENBLATT DJ, VON MOLTKE LL, JEROLD S, SHADER RI: Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. J. Clin. Psychopharmacol. (1999) 19(5 Suppl. 1):S23-S35.
69. GLEASON OC, YATES WR, ISBELL MD, PHILIPSEN MA: An open trial of citalopram for major depression in patients with hepatitis C. J. Clin. Psychiatry (2002) 63(3):194-198. (Pubitemid 34407077)
70. BURKE WJ, ROTHSCHILD T, DE SWART H: Safety experience with escitalopram in the treatment of elderly patients with depression. Annual Scientific Meeting of the American Association for Geriatric Psychiatry, Honolulu, HI, May 2003.
71. GURLAND BJ, KATZ S, CHEN J: Index of affective suffering. Linking a classification of depressed mood to impairment in quality of life. Am. J. Geriatr. Psychiatry. (1997) 5:192-210. (Pubitemid 27276795)
72. KARLSSON I, GODDERIS J, AUGUSTO DE MENDONCA LIMA C et al.: A randomized, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia. Int. J. Geriatr. Psychiatry (2000) 15:295-305. (Pubitemid 30315744)
73. POLLOCK BG, MULSANT BH, ROSEN J et al.: Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am. J. Psychiatry (2002) 159:460-465. (Pubitemid 34184743)
74. GREENBLATT DJ, VON MOLTKE LL, HARMATZ JS, SHADER RS: Drug interactions with newer antidepressants: role of human cytochromes P450. J. Clin. Psychiatry (1998) 59(Suppl. 15):19-27. (Pubitemid 28467474)
75. BUCHBERGER R, WAGNER W: Fluvoxamine: safety profile in extensive post-marketing surveillance. Pharmacopsychiatry (2002) 35(3):101-108. (Pubitemid 34651916)
76. STAHL SM: Newer depressants and mood stabilizers. In: Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (2nd edn). Cambridge University Press, New York (2000):245-295.
77. SPINA E, SCORDO MG: Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging (2002) 19(4):299-320. (Pubitemid 34686722)
78. DEVANE DL, POLLACK BG: Pharmacokinetic considerations of antidepressant use in the elderly. J. Clin. Psychiatry (1999) 60(Suppl.):38-44.
79. BARBHAIYA RH, BUCH, GREENE DS: A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J. Clin. Pharmacol. (1996) 16:19-25. (Pubitemid 26060752)
80. ABERNETHY DR, BARBEY JT, FRANC J et al.: Loratadine and terfenadine interaction with nefazodone: both antihistamines are associated with QTc prolongation. Clin. Pharmacol. Ther. (2001) 69(3):96-103. (Pubitemid 32225407)
81. SCHWETZ BA: Warning on serzone. JAMA (2002) 287(9):1103.
82. SOMMER BR: Personal communication with Bristol-Myers Squibb, Drug Information, Medical Communications Division, Stanford, CA, USA (August 6 2002).
83. SAIZ-RUIZ J, IBANEZ A, DIAZ-MARSA M et al.: Nefazodone in the treatment of elderly patients with depressive disorders: a prospective, observational study. CNS Drugs (2002) 16(9):635-643.
84. PETROVIC M, PEVERNAGIE D, VAN DEN NOORTGATE N, MARIMAN A, MICHIELSEN W, AFSCHRIFT M: A programme for short-term withdrawal from benzodiazepines in geriatric hospital inpatients: success rate and effect on subjective sleep quality. Int. J. Geriatr. Psychiatry (1999) 14:754-760. (Pubitemid 29450288)
85. SALETU-ZYHLARZ GM, ABU-BAKR MH, ANDERER P et al.: Insomnia related to dysthymia: polysomnographic and psychometric comparison with normal controls and acute therapeutic trials with trazodone. Neuropsychobiology (2001) 44(3):139-149. (Pubitemid 34701621)
86. COSTABILE RA, SPEVAK M: Oral trazodone is not effective therapy for erectile dysfunction: a double-blind, placebo-controlled trial. J. Urol. (1999) 161:1819-1822. (Pubitemid 29420740)
87. AMORE M, RICCI M, ZANARDE R, PEREZ J, FERRARI G: Long-term treatment of geropsychiatric depressed patients with venlafaxine. J. Affect. Disord. (1997) 46:293-296. (Pubitemid 28165954)
88. TASMUTH T, HARTEL B, KALSO E: Venlafaxine in neuropathic pain following treatment of breast cancer. Eur. J. Pain. (2002) 6(1):17-24.
89. STAAB JP, EVANS DL: Efficacy of venlafaxine in geriatric depression. Depress. Anxiety (2000) 12(Suppl.):63-68.
90. KIRBY D, HARRIGAN S, AMES D: Hyponatraemia in elderly psychiatric patients treated with selective serotonin reuptake inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit. Int. J. Geriatr. Psychiatry (2002) 17:231-237. (Pubitemid 34232595)
91. CROFT H, SETTLE JR. E, HOUSER T, BATEY SR, DONAHUE RM, ASCHER JA: A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin. Ther. (1999) 21(4):643-658. (Pubitemid 29252088)
92. NIEUWSTRATEN CE, DOLOVICH LR: Bupropion versus selective serotonin reuptake inhibitors for treatment of depression. Ann. Pharmacother. (2001) 35:1608-1613. (Pubitemid 34027464)
93. HESSE LM, VENKATAKRISHNAN K, COURT MH et al.: CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab. Dispos. (2000) 28(10):1176-1183.
94. FENN H, KETTER TA: Personal communication, Stanford, CA, USA (2002).
95. WEIHS KL, SETTLE EC, BATEY SR, HOUSER TL, DONAHUE RMJ, ASCHER JA: Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J. Clin. Psychiatry (2000) 61(3):196-202. (Pubitemid 30214516)
96. JEFFERSON JW: Cardiovascular effects of bupropion. J. Clin. Psychiatry (1993) 11(monograph):43-48.
97. SCHATZBERG AF, KREMER C, RODRIGUEZ H, MURPHY GM Jr: Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am. J. Geriatr. Psychiatry (2002) 10(5)541-550. (Pubitemid 34984390)
98. SHIMADA T, YAMAZAKI H, MIMURA M, INUI Y, GUENGERICH FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. (1994) 270:414-423. (Pubitemid 24229655)